Strategies for treating liver metastasis from gastric cancer

Surgery Today

Volumn 40, Issue 4, 2010, Pages 287-294

  Kakeji, Yoshihiro ^a   Morita, Masaru ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Adjuvant chemotherapy; Gastric cancer; Hepatic resection; Liver metastasis

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEFITINIB; INTERCELLULAR ADHESION MOLECULE 1; IRINOTECAN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MITOMYCIN C; SCATTER FACTOR RECEPTOR; TAXANE DERIVATIVE; TUMOR MARKER; VASCULOTROPIN;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LIVER METASTASIS; LIVER RESECTION; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; PREOPERATIVE EVALUATION; RADIOFREQUENCY ABLATION; REVIEW; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR ABLATION; LIVER TUMOR; METASTASIS; PATHOLOGY; STOMACH TUMOR;

COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; STOMACH NEOPLASMS;

EID: 77953954523     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-009-4152-0     Document Type: Review

References (87)

1. American Cancer Society. Global cancer facts and figures 2007. http://www.cancer.org/downloads/STT/Global-Facts-and-Figs.-2007-rev2.pdf. Accessed 16 Jun 2009.
2. Ministry of Health, Labor and Welfare, Japan. Figures for vital statistics in 2007. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/ kakutei07/hyo7.html. Accessed 16 Jun 2009.
3. Sasako M, Saka M, Fukagawa T, Katai H, Sano T. Modern surgery for gastric cancer - Japanese perspective. Scand J Surg 2006;95:232-5.
4. Douglass HO Jr, Hundahl SA, Macdonald JS, Khatri VP. Gastric cancer: D2 dissection or low Maruyama Index-based surgery - a debate. Surg Oncol Clin N Am 2007;16:133-55.
5. Sano T. Tailoring treatments for curable gastric cancer. Br J Surg 2007;94:263-4.
6. Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, et al. D2 lymphadenectomy alone or with paraaortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-62.
7. Hu JK, Yang K, Zhang B, Chen XZ, Chen ZX, Chen JP. D2 plus para-aortic lymphadenectomy versus standardized D2 lymphadenectomy in gastric cancer surgery. Surg Today 2009;39:207-13.
8. Marrelli D, Roviello F, De Stefano A, Fotia G, Gilberto C, Garosi L, et al. Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection. J Am Coll Surg 2004;198:51-8.
9. Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, et al. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 2002;235:86-91.
10. Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K, et al. Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery 2003;133:507-11.
11. Sakamoto Y, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T, et al. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol 2007;95:534-9.
12. Nakanishi H, Yasui K, Ikehara Y, Yokoyama H, Munesue S, Kodera Y, et al. Establishment and characterization of three novel human gastric cancer cell lines with differentiated intestinal phenotype derived from liver metastasis. Clinical & Experimental Metastasis 2005;22:137-47.
13. Terracciano LM, Glatz K, Mhawech P. Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma: An immunohistochemical and molecular study of eight cases. Am J Surg Pathol 2003;27:1302-12.
14. Adachi Y, Tsuchihashi J, Shiraishi N. AFP-producing gastric carcinoma: Multivariate analysis of prognostic factors in 270 patients. Oncology 2003;65:95-101.
15. Gao YB, Zhang DF, Jin XL, Xiao JC. Preliminary study on the clinical and pathological relevance of gastric hepatoid adenocarcinoma. J Dig Dis 2007;8:23-8.
16. Maehara Y, Moriguchi S, Kakeji Y, Kohnoe S, Korenaga D, Haraguchi M, et al. Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination or liver metastasis. Surgery 1991;110:820-3.
17. Amemiya H, Kono K, Itakura J. c-Met expression in gastric cancer with liver metastasis. Oncology 2002;63(3):286-96.
18. Kakeji Y, Koga T, Sumiyoshi Y, Shibahara K, Oda S, Maehara Y, et al. Clinical signifi cance of vascular endothelial growth factor expression in gastric cancer. J Exp Clin Cancer Res 2002;21: 125-9.
19. Maruo Y, Gochi A, Kaihara A. ICAM-1 expression and the soluble ICAM-1 level for evaluating the metastatic potential of gastric cancer. Int J Cancer 2002;100(4):486-90.
20. Mayer B, Lorenz C, Babic R. Expression of leukocyte cell adhesion molecules on gastric carcinomas: Possible involvement of LFA-3 expression in the development of distant metastases. Int J Cancer 1995;64(6):415-23.
21. Giordano S, Ponzetto C, Di Renzo MF, Cooper CS, Comoglio PM. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 1989;339:155-6.
22. Giordano S, Di Renzo MF, Narsimhan RP, Cooper CS, Rosa C, Comoglio PM. Biosynthesis of the protein encoded by the c-met protooncogene. Oncogene 1989;4:1383-8.
23. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-41.
24. Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991;47:211-8.
25. Simmons D, Makgoba MW, Seed B. ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM. Nature 1988;331:624-7.
26. Marlin SD, Spriger TA. Purifi ed intercellular adhesion molecule 1 (ICAM-1) is a ligand for lymphocyte function-associated antigen-1 (LFA-1). Cell 1987;51:813-9.
27. Dustin ML, Rothlein R, Bhan AK, Dimarello CA, Springer TA. Induction by IL-1 and interferon-gamma: tissue distribution, biochemistry and function of a natural adherence molecule (ICAM-1). J Immunol 1986;137:245-54.
28. Staunton DE, Marlin SD, Stratowa C, Dustin ML, Springer TA. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell 1988;52:925-33.
29. Makgoba MW, Sanders ME, Shaw S. The CD-2-LFA-3 and LFA 1-ICAM pathways: relevance to T-cell recognition. Immunol Today 1989;10:417-22.
30. Garcia-Barcina M, Lukomska B, Gawron W, Winnock M, Viral-Vanaccocha F, Bioulac-Sage P, et al. Expression of cell adhesion molecules on liver-associated lymphocytes and their ligands on sinusoidal lining cells in patients with benign or malignant disease. Am J Pathol 1995;146:12406-13.
31. Volpes R, van der Oord JJ, Desmet VJ. Immunohistochemical study of adhesion molecules in liver infl ammation. Hepatology 1990;12:59-65.
32. Nakanishi H, Yasui K, Yamagata S. Establishment and characterization of a new spontaneous metastasis model of human gastric carcinoma in nude mice. Jpn J Cancer Res 1991; 82(8):927-33.
33. Yamaguchi K, Ura H, Yasoshima T. Liver metastatic model for human gastric cancer established by orthotopic tumor cell implantation. World J Surg 2001;25(2):131-7.
34. Shen XH, Jin WN, Cui H, Cui X, Noh SH, Chung HC, et al. Cellular adjustment of gastric cancer for hepatic metastasis in successive orthotopic implantation model. Cancer Biol Ther 2006; 5:1313-9.
35. Koga S, Kawaguchi H, Kishimoto H, Tanaka K, Miyano Y, Kimura O, et al. Therapeutic signifi cance of noncurative gastrectomy for gastric cancer with liver metastasis. Am J Surg 1980;140:356-9.
36. Shirabe K, Shimada M, Matsumata T, Higashi H, Yakeishi Y, Wakiyama S, et al. Analysis of the prognostic factors for liver metastasis of gastric cancer after hepatic resection: a multi-institutional study of the indications for resection. Hepatogastroenterology 2003;50:1560-3.
37. Ochiai T, Sasako M, Mizuno S, Kinoshita T, Takayama T, Kosuge T, et al. Hepatic resection for metastatic tumours from gastric cancer: analysis of prognostic factors. Br J Surg 1994;81:1175-8.
38. Koga R, Yamamoto J, Ohyama S, Saiura A, Seki M, Seto Y, et al. Liver resection for metastatic gastric cancer: experience with 42 patients including eight long-term survivors. Jpn J Clin Oncol 2007;37:836-42.
39. Miyazaki M, Itoh H, Nakagawa K, Ambiru S, Shimizu H, Togawa A, et al. Hepatic resection of liver metastases from gastric carcinoma. Am J Gastroenterol 1997;92:490-3.
40. Ambiru S, Miyazaki M, Ito H, Nakagawara K, Shimizu H, Yoshidome H, et al. Benefi ts and limits of hepatic resection for gastric metastases. Am J Surg 2001;181:279-83.
41. Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, et al. Survival benefi t of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol 2008;19:1146-53.
42. Chen MH, Yang W, Yan K, Gao W, Dai Y, Wang YB, et al. Treatment efficacy of radiofrequency ablation of 338 patients with hepatic malignant tumor and the relevant complications. World J Gastroenterol 2005;11:6395-401.
43. Iannitti DA, Dupuy DE, Mayo-Smith WW, Murphy B. Hepatic radiofrequency ablation. Arch Surg 2002;137:422-6; discussion 427.
44. Yamakado K, Nakatsuka A, Takaki H, Mori Y, Tonouchi H, Kusunoki M, et al. Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer. J Vasc Interv Radiol 2005; 16:1747-51.
45. Carditello A, Scisca C, Stilo F, Parisi A, Basile M. The possible role of radiofrequency as complementary treatment of locally advanced gastric cancer. Ann Ital Chir 2005;76:39-41.
46. Gannon CJ, Curley SA. The role of focal liver ablation in the treatment of unresectable primary and secondary malignant liver tumors. Semin Radiat Oncol 2005;15:265-72.
47. An JY, Kim JY, Choi MG, Noh JH, Choi D, Sohn TS, et al. Radiofrequency ablation for hepatic metastasis from gastric adenocarcinoma. Yonsei Med J 2008;49:1046-51.
48. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5- fluorouracil derivative (S-1) directed to the potentiation of the tumour selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57.
49. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 1999;57:202-10.
50. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine aniticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34:1715-20.
51. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer. (JCOG9912) Proc Am Soc Clin Oncol 2007;LBA4513 (abstract).
52. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-21.
53. Imamura H, Iishi H, Tsuburaya A, Hatake K, Imamoto H, Esaki T, et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). Proc Gastrointestinal Cancers Symposium 2008;4 (abstract).
54. Japan Clinical Cancer Research Organization. A Phase III study of docetaxel and S-1 versus S-1 in the treatment of advanced gastric cancer. https://center.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action= brows&recptno=R000000317&type=summary&language=J. Accessed 16 Jun 2009.
55. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006;12:3402-7.
56. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil in comparison to cisplatin and fluorouracil as first line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-7.
57. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
58. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-673.
59. Ganeshan A, Upponi S, Hon LQ, Warakaulle D, Uberoi R. Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol 2008;19:847-51.
60. Yonemura Y, Matsuki N, Sakuma H, Katayama K, Sawa T, Fujimura T, et al. Effect of intra-hepatoarterial infusion of MMC and CDDP for gastric cancer patients with liver metastases. Surg Today 1992;22:253-9.
61. Arai Y, Endo T, Sone Y, Tohyama N, Inaba Y, Ariyoshi Y, et al. Management of patients with unresectable liver metastases from colorectal and gastric cancer employing an implantable port system. Cancer Chemother Pharmacol 1992;31(suppl I):S99-102.
62. Ojima H, Ootake S, Yokobori T, Mochida Y, Hosouchi Y, Nishida Y, et al. Treatment of multiple liver metastasis from gastric carcinoma. World J Surg Oncol 2007;5:70.
63. Kumada T, Arai Y, Itoh K, Takayasu Y, Nakamura K, Ariyoshi Y, et al. Phase II study of combined administration of 5- fluorouracil, epirubicin and mitomycin-c by hepatic artery infusion in patients with liver metastases of gastric cancer. Oncology 1999;57:216-23.
64. Johansson, C-J. Pharmacokinetic rationale for chemotherapeutic drugs combined with intra-arterial degradable starch microspheres (Spherex(R)). Clin Pharmacokinet 1996;31:231-40.
65. Hirasawa T, Asahara S, Fujisaki S, Kuraoka K, Takano K, Kamei A, et al. Transcatheter arterial chemoembolization (TACE) using degradable starch microspheres (DSM) for metastatic liver tumors in patients with gastric cancer (in Japanese with English abstract). J Jpn Soc Gastroenterol 2008;105:367-72.
66. Chang YC, Nagasue N, Abe S, Taniura H, Kumar DD, Nakamura T. Comparison between the clinicopathologic features of AFPpositive and AFP-negative gastric cancers. Am J Gastroenterol 1992;87:321-5.
67. Mihmanli M, Dilege E, Demir U, Coskun H, Eroglu T, Uysalol MD. The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterology 2004;51:1544-7.
68. Reynoso G, Chu TM, Holyoke D, Cohen E, Nemoto T, Wang JJ, et al. Carcinoembryonic antigen in patients with different cancers. JAMA 1972;220:361-5.
69. Nakagoe T, Sawai T, Tsuji T, Jibiki M, Nanashima A, Yamaguchi H, et al. Pre-operative serum levels of sialyl Tn antigen predict liver metastasis and poor prognosis in patients with gastric cancer. Eur J Surg Oncol 2001;27:731-9.
70. Santeusanio G, Peronace L, Castagna G, De Muro G, Santi D, D'Orazio A, et al. Immunohistochemical study of carcinoembryonic antigen (CEA) in gastric tumors: correlation with preoperative serum levels, histologic type, and grade of anaplasia of the tumor. J Surg Oncol 1988;37:13-9.
71. Maehara Y, Kusumoto T, Takahashi I, Kakeji Y, Baba H, Akazawa K, et al. Predictive value of preoperative carcinoembryonic antigen levels for the prognosis of patients with welldifferentiated gastric cancer. A multivariate analysis. Oncology 1994;51:234-7.
72. Ishigami S, Natsugoe S, Hokita S, Che X, Tokuda K, Nakajo A, et al. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J Clin Gastroenterol 2001;32:41-4.
73. Choi SR, Jang JS, Lee JH, Roh MH, Kim MC, Lee WS, et al. Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy. Dig Dis Sci 2006; 51:2081-6.
74. Korenaga D, Saeki H, Mawatari K, Orita H, Maekawa S, Ikeda T, et al. Serum carcinoembryonic antigen concentration doubling time correlates with tumor biology and life expectancy in patients with recurrent gastrointestinal carcinoma. Arch Surg 1997;132: 188-94.
75. Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS, et al. Follow-up study of peripheral blood carcinoembryonic antigen mRNA using reverse transcription-polymerase chain reaction as an early marker of clinical recurrence in patients with curatively resected gastric cancer. Am J Clin Oncol 2005;28:24-9.
76. Motoyama T, Aizawa K, Watanabe H, Fukase M, Saito K. α-Fetoprotein- producing gastric carcinomas: A comparative study of three different subtypes. Acta Pathol Jpn 1993;43: 654-61.
77. Kono K, Amemiya H, Sekikawa T, Iizuka H, Takahashi A, Fujii H, et al. Clinicopathologic features of gastric cancers producing alpha-fetoprotein. Dig Surg 2002;19:359-65.
78. Amemiya H, Kono K, Mori Y, Takahashi A, Ichihara F, Iizuka H, et al. High frequency of c-Met expression in gastric cancers producing α-fetoprotein. Oncology 2000;59:145-51.
79. Matsumoto K, Nakamura T. Hepatocyte growth factor as a tissue organizer for organogenesis and regeneration. Biochem Biophys Res Commun 1997;239:639-44.
80. Matsumoto K, Nakamura T. Hepatocyte growth factor: molecular structure, roles in liver regeneration and other biological functions. Crit Rev Oncogen 1992;3:27-54.
81. Koide N, Nishio A, Igarashi J, Kajikawa S, Adachi W, Amano J. Alpha-fetoprotein-producing gastric cancer: Histochemical analysis of cell proliferation, apoptosis and angiogenesis. Am J Gastroenterol 1999;94:1658-63.
82. Fujii H, Ichikawa K, Takagaki T, Nakanishi Y, Ikegami M, Hirose S, et al. Genetic evolution of [alpha] fetoprotein producing gastric cancer. J Clin Pathol 2003;56:942-9.
83. Nakagoe T, Sawai T, Tsuji T, Jibiki M, Nanashima A, Yamaguchi H, et al. Difference in prognostic value between sialyl Lewisa and sialyl Lewisx antigen levels in the preoperative serum of gastric cancer patients. J Clin Gastroenterol 2002;34:408-15.
84. Kjeldsen T, Clausen H, Hirohashi S, Ogawa T, Iijima H, Hakomori S. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl- 2,6-N acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res 1988;48:2214-20.
85. Takahashi I, Maehara Y, Kusumoto T, Yoshida M, Kakeji Y, Kusumoto H, et al. Predictive value of preoperative serum sialyl Tn antigen levels in prognosis of patients with gastric cancer. Cancer 1993;72:1836-40.
86. Nakagoe T, Sawai T, Tsuji T, Jibiki M, Nanashima A, Yamaguchi H, et al. Pre-operative serum levels of sialyl Tn antigen predict liver metastasis and poor prognosis in patients with gastric cancer. Eur J Surg Oncol 2001;27:731-9.
87. Yokoyama H, Ikehara Y, Kodera Y, Ikehara S, Yatabe Y, Mochizuki Y, et al. Molecular basis for sensitivity and acquired resistance to gefi tinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer 2006;95:1504-13.